

Amendments to the Claims:

Please rewrite the claims as follows:

1. (Original) Pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance.
2. (Original) Pharmaceutical formulation according to claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, wherein the formulation is in the form of a tablet with a content of at least one flow regulator.
3. (Original) Pharmaceutical formulation according to claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, wherein the formulation is in the form of a filling for capsules.
4. (Original) Pharmaceutical formulation according to claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, wherein the formulation is in the form of a dragée, effervescent tablet, suppository or granulate.
5. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 comprising flutamide of a particle size such as is formed in the synthesis process with subsequent purification step(s).
6. (Original) Formulation according to claim 5 comprising flutamide of a particle size such as is formed in the synthesis process with recrystallisation as a subsequent purification step.
7. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 comprising flutamide of a mean particle size greater than the mean particle size of flutamide that, with an initial particle size of from 5 to 240 μm , has been subjected to a milling operation.

8. (Currently Amended) Formulation according to ~~at least one of claims 1 to 7~~ claim 1 comprising flutamide in which the size of 50 % of the flutamide particles (X50 value) is greater than 20 μm .

9. (Original) Formulation according to claim 8 comprising flutamide in which the size of 50 % of the flutamide particles (X50 value) is greater than 26 μm .

10. (Currently Amended) Formulation according to ~~at least one of claims 1 to 7~~ claim 1 comprising flutamide in which the size of 90 % of the flutamide particles (X90 value) is greater than 60 μm .

11. (Original) Formulation according to claim 10 comprising flutamide in which the size of 90 % of the flutamide particles (X90 value) is greater than 130 μm .

12. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 comprising flutamide of a specific surface area of less than 2.50 m^2/cm^3 .

13. (Original) Formulation according to claim 12 comprising flutamide of a specific surface area of less than 1.50 m^2/cm^3 .

14. (Original) Formulation according to claim 13 comprising flutamide of a specific surface area of less than 0.35 m^2/cm^3 .

15. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 comprising flutamide in the form of the free acid amide and/or of a pharmaceutically acceptable solvate.

16. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 comprising at least one surface-active substance selected from the group formed by
- anionic compounds,
- cationic compounds and

- non-ionic surfactants.

17. (Original) Formulation according to claim 16 comprising sodium dodecylsulphate as surface-active substance.

18. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 with a ratio by weight of flutamide : surface-active substance(s) of from 5 : 1 to 30 : 1.

19. (Original) Formulation according to claim 18 with a ratio by weight of flutamide : surface-active substance(s) of from 5 : 1 to 20 : 1.

20. (Original) Formulation according to claim 19 with a ratio by weight of flutamide : surface-active substance(s) of from 10 : 1 to 15 : 1.

21. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 in the form of an unshaped mixture or in the form of an article that has been subjected to shaping.

22. (Original) Formulation according to claim 21 with a content of from 50 to 2000 mg of flutamide.

23. (Original) Formulation according to claim 22 with a content of from 50 to 500 mg of flutamide.

24. (Original) Formulation according to claim 23 with a content of from 100 to 200 mg of flutamide.

25. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 with a content of at least one excipient from the group formed by inorganic fillers, organic fillers, binders, glidants, lubricants, flow regulators and/or disintegrants.

26. (Currently Amended) Formulation according to ~~at least one of the preceding claims~~ claim 1 with a content of at least one further pharmaceutical active ingredient besides flutamide.

27. (Currently Amended) Process for the preparation of a pharmaceutical formulation according to ~~at least one of claims 1 and 5 to 26~~ claim 1 comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, in which the flutamide is subjected to an intensive mixing process with the at least one surface-active substance.

28. (Currently Amended) Process for the preparation of a pharmaceutical formulation according to claim 2, ~~3 or 4~~ comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, in which the flutamide is subjected to an intensive mixing process with the at least one surface-active substance, and the mixture obtained is further processed to form a formulation according ~~claim 2, 3 or 4~~.

29. (Currently Amended) Process according to claim 27 ~~or 28~~ in which mixing is carried out at a temperature of from 0 to 40°C.

30. (Original) Process according to claim 29 in which mixing is carried out at room temperature.

31. (Currently Amended) Process according to ~~at least one of claims 27 to 30~~ claim 27 in which one or more excipients are admixed using a forced-action mixer or using a free-fall mixer.

32. (Currently Amended) Process according to ~~at least one of claims 27 to 34~~ claim 27 in which one or more further pharmaceutical active ingredients, which are not flutamide, are admixed using a forced-action mixer or a free-fall mixer.

33. (Currently Amended) Process according to ~~at least one of claims 27 and 29 to 32~~ claim 27 in which the mixture obtained is further processed to form tablets, capsules, dragées, effervescent tablets, suppositories or a granulate.

34. (Currently Amended) Process according to claim 28-and/or according to claim 33 in which the mixture obtained is subject to direct tableting.

35. (Currently Amended) Process according to claim 28-and/or according to claim 33 in which the granulate is further processed to form tablets.

36. (Currently Amended) Pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance, producible in accordance with a process according to ~~at least one of claims 27 to 35~~ claim 27.